Tapewire

Nasdaq · USD

OLMA

Olema Pharmaceuticals, Inc.

Export transactions ↓
Tapewire entity
613
SEC CIK
0001750284
Parsed reports
244

Last 12 months

Inside the activity.

0 purchase rows · 25 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 2025011
Jan 202609
Feb 202600
Mar 202603
Apr 202600
May 202600
Jun 202600
Jul 202602
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 19, 2020 Filed Nov 19, 2020 23:41 UTC
Bohen SeanDirector · President and CEO
GrantStock Option (Right to Buy) · Derivative 82,931 $0.00 Strike: $4.82 $0.00
Disclosure

SEC source: 0001209191-20-059509 · doc4.xml · derivative · entry 2

Bohen Sean · CIK 0001831218 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,931

Underlying: Common Stock · 82,931 shares

Expires 2030-09-18

F1 · derivative.exercise_date: 20,732 of the shares subject to the option vest on September 1, 2021 and 20,733 of the shares subject to the option vest on January 1 of each of 2022, 2023 and 2024, subject to the Reporting Person's continuous service on each applicable vesting date.

Read SEC document
September 18, 2020 Filed Nov 20, 2020 00:00 UTC GrantStock Option (Right to Buy) · Derivative 56,964 $0.00 Strike: $4.82 $0.00
Disclosure

SEC source: 0001209191-20-059526 · doc4.xml · derivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,964

Underlying: Common Stock · 56,964 shares

Expires 2030-09-17

F1 · derivative.exercise_date: The shares subject to the option are fully vested.

Read SEC document
September 18, 2020 Filed Nov 19, 2020 23:56 UTC GrantStock Option (Right to Buy) · Derivative 56,964 $0.00 Strike: $4.82 $0.00
Disclosure

SEC source: 0001209191-20-059522 · doc4.xml · derivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,964

Underlying: Common Stock · 56,964 shares

Expires 2030-09-17

F1 · derivative.exercise_date: The shares subject to the option are fully vested.

Read SEC document
September 16, 2020 Filed Nov 19, 2020 23:42 UTC Exercise / conversionStock Option (Right to Buy) · Derivative 83,876 $0.00 Strike: $4.41 $0.00
Disclosure

SEC source: 0001209191-20-059510 · doc4.xml · derivative · entry 3

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,876 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from August 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable.

Read SEC document
September 16, 2020 Filed Nov 19, 2020 23:42 UTC Exercise / conversionCommon Stock 83,876 $4.41 $369,557.66
Disclosure

SEC source: 0001209191-20-059510 · doc4.xml · nonDerivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,876

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 12, 2020 Filed Nov 19, 2020 23:43 UTC
Harmon CyrusDirector · Chief Technology Officer
GrantStock Option (Right to Buy) · Derivative 227,859 $0.00 Strike: $4.82 $0.00
Disclosure

SEC source: 0001209191-20-059512 · doc4.xml · derivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,859

Underlying: Common Stock · 227,859 shares

Expires 2030-09-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from September 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
August 12, 2020 Filed Nov 19, 2020 23:42 UTC GrantStock Option (Right to Buy) · Derivative 83,876 $0.00 Strike: $4.41 $0.00
Disclosure

SEC source: 0001209191-20-059510 · doc4.xml · derivative · entry 2

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,876

Underlying: Common Stock · 83,876 shares

Expires 2030-08-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from August 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable.

Read SEC document
August 12, 2020 Filed Nov 19, 2020 23:42 UTC
CLARK IAN TDirector
GrantStock Option (Right to Buy) · Derivative 209,690 $0.00 Strike: $4.41 $0.00
Disclosure

SEC source: 0001209191-20-059511 · doc4.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,690

Underlying: Common Stock · 209,690 shares

Expires 2030-08-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from August 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable.

Read SEC document
June 15, 2020 Filed Nov 19, 2020 18:55 UTC
Kushner Peter J.Chief Scientific Officer
GrantCommon Stock 143,472 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-059521 · doc4.xml · nonDerivative · entry 1

Kushner Peter J. · CIK 0001831217 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,072,752

Read SEC document
June 15, 2020 Filed Nov 19, 2020 18:47 UTC
Kovacs Shane William CharlesCh. Operating & Financial Off.
GrantCommon Stock 358,680 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-059517 · doc4.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · Ch. Operating & Financial Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,680

Read SEC document
June 15, 2020 Filed Nov 19, 2020 23:59 UTC
Myles David C.Chief Development Officer
GrantCommon Stock 143,472 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-059524 · doc4.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 591,821

Read SEC document
June 15, 2020 Filed Nov 19, 2020 23:43 UTC
Harmon CyrusDirector · Chief Technology Officer
GrantCommon Stock 143,472 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-059512 · doc4.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,040,172

Read SEC document
June 10, 2020 Filed Nov 19, 2020 23:44 UTC
Horn KinneyChief Business Officer
GrantStock Option (Right to Buy) · Derivative 252,060 $0.00 Strike: $2.06 $0.00
Disclosure

SEC source: 0001209191-20-059513 · doc4.xml · derivative · entry 1

Horn Kinney · CIK 0001831215 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,060

Underlying: Common Stock · 252,060 shares

Expires 2030-06-09

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
June 01, 2020 Filed Nov 20, 2020 00:01 UTC PurchaseSeries B Convertible Preferred Stock · Derivative 339,578 $4.71 $1,599,989.66
Disclosure

SEC source: 0001209191-20-059528 · doc4.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 339,578

Underlying: Common Stock · 339,578 shares

Expires not disclosed

F1 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.

F1 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.

F1 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.

F2 · ownership.nature: The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunies GP, LLC ("Logos GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Read SEC document
June 01, 2020 Filed Nov 20, 2020 23:43 UTC Amendment PurchaseSeries B Convertible Preferred Stock · Derivative 339,578 $4.71 $1,599,989.66
Disclosure

SEC source: 0001209191-20-059760 · doc4a.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,400,761

Underlying: Common Stock · 339,578 shares

Expires not disclosed

F1 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.

F1 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.

F1 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.

F2 · ownership.nature: The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.